



Flexion Therapeutics, Inc.  
 Investor Relations Department  
 10 Mall Road  
 Suite 301  
 Burlington, MA 01803  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

**NASDAQ: FLXN**

Last Trade:	25.22
Trade Time:	4:00 PM ET Dec 15, 2017
Change:	0.77 <span style="color: green;">▲</span> (+3.149%)
Day Range	24.26 - 25.67
52-Week Range	16.51 - 32.25
Volume	3,696,499

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Dec 13, 2017*  
[Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee](#)
- Dec 11, 2017*  
[Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer](#)
- Dec 7, 2017*  
[Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\) in Bilateral Osteoarthritis of the Knee](#)
- Dec 6, 2017*  
[Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference](#)
- Dec 4, 2017*  
[Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\) \(4\)](#)

**Financials** [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 10, 2017*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*  
[Quarterly Report \(10-Q\)](#)